The Real Test for Gardasil: Money, not Morals
This article was originally published in RPM Report
Executive Summary
The real test for Gardasil isn't FDA approval or the Advisory Committee on Immunization Practices' recommendation for universal vaccination. In the long run, Gardasil's commercial success will be depend more on the future of the Vaccines for Children Act--and how long the government wants to continue to sign blank checks for childhood vaccinations.
You may also be interested in...
Gardasil Pushes Vaccine Prices--and Markets--to New Heights
The Gardasil launch is arguably the event with the greatest impact on the public perception of the new opportunities in vaccines, since it offers the promise of preventing future cervical cancers by vaccinating young adolescent girls. The commercialization of Gardasil has been front page news throughout the summer.
Medicare Part B vs. Part D
Drug companies are struggling with which reimbursement strategy to pursue. It
Mind Your Bs and Ds
There is a new variable to consider in drug development: which Medicare coverage system is more desirable: the Part B system for physician-administered drugs or Part D for the traditional retail market. But why choose one when you can play in both?